These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 5146109)

  • 1. [Griseofulvin administered for an indeterminate time in the therapy of systemic scleroderma and Raynaud's syndrome].
    Giordano M; Capelli L; Ara M; Tirri G
    Reumatismo; 1971; 23(2):82-92. PubMed ID: 5146109
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin temperature changes in Raynaud's disease after griseofulvin.
    Charles CR; Carmick ES
    Arch Dermatol; 1970 Mar; 101(3):331-6. PubMed ID: 5414890
    [No Abstract]   [Full Text] [Related]  

  • 3. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies in 25 patients with progressive systemic scleroderma treated by long-term administration of griseofulvin].
    Giordano M; Ara M; Capelli L; Tirri G; Pettinato G; Vatti M
    Minerva Med; 1973 Jun; 64(46):2451-66. PubMed ID: 4579328
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sympatholytic effect of intra-arterial reserpine in sclerodermia and Raynaud's disease].
    Acevedo A; Palacios JM; López R; Palma F
    Rev Med Chil; 1984 Jun; 112(6):553-8. PubMed ID: 6515168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of Panergon therapy in Raynaud syndrome within the scope of progressive scleroderma].
    Bosmanský K; Tauchmannová H; Lukác J; Zitnan D
    Z Rheumatol; 1985; 44(5):242-5. PubMed ID: 4082792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Raynaud's syndrome: diagnosis and therapy].
    Mahler F
    Ther Umsch; 1985 Oct; 42(10):671-7. PubMed ID: 3909486
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of Capoten in systemic scleroderma].
    Guseva NG; Anikina NV; Shcherbakov AB
    Ter Arkh; 1992; 64(5):100-2. PubMed ID: 1455361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic connective tissue diseases in India, VI. Raynaud's disease and pre-progressive systemic sclerosis (Pre-PSS).
    Malaviya AN; Narayanan K; Tiwari SC; Khan KM; Raina V; Pande JN
    J Assoc Physicians India; 1983 Oct; 31(10):625-8. PubMed ID: 6671930
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
    Ramos-Casals M; Brito-Zerón P; Nardi N; Claver G; Risco G; Parraga FD; Fernandez S; Julià M; Font J
    Rheumatology (Oxford); 2004 Nov; 43(11):1454-6. PubMed ID: 15502001
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 18. A double-blind clinical trial of griseofulvin in patients with Raynaud's phenomenon.
    Sabri S; Higgins RF; Roberts VC; Cotton LT; Williams DI; Wilson LC
    Postgrad Med J; 1973 Sep; 49(575):641-3. PubMed ID: 4596620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
    Kumar N; Griffiths B; Allen J
    J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
    [No Abstract]   [Full Text] [Related]  

  • 20. Raynaud's phenomenon and scleroderma.
    Harper FE; LeRoy EC
    Compr Ther; 1981 Feb; 7(2):45-51. PubMed ID: 6163587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.